- Home
- ARDX
ARDX
Ardelyx Inc.
as 02-21-2025 4:00pm EST
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 1.4B | IPO Year: | 2014 |
| Target Price: | $9.93 | AVG Volume (30 days): | 3.6M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.32 - $9.83 | Next Earning Date: | 02-20-2025 |
| Revenue: | $333,615,000 | Revenue Growth: | 168.06% |
| Revenue Growth (this year): | 169.3% | Revenue Growth (next year): | 14.87% |
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | ARDX | President & CEO | Jan 31 '25 | Sell | $5.36 | 41,666 | $223,354.76 | 1,108,719 | |
| MOTT DAVID M | ARDX | Director | Jan 21 '25 | Buy | $4.99 | 199,000 | $992,671.70 | 1,937,765 | |
| RAAB MICHAEL | ARDX | President & CEO | Jan 7 '25 | Sell | $5.31 | 41,666 | $221,308.96 | 1,108,719 | |
| MOTT DAVID M | ARDX | Director | Dec 19 '24 | Buy | $4.67 | 213,300 | $996,580.26 | 1,937,765 | |
| RAAB MICHAEL | ARDX | President & CEO | Dec 10 '24 | Sell | $5.26 | 25,000 | $131,620.00 | 1,108,719 | |
| RAAB MICHAEL | ARDX | President & CEO | Nov 25 '24 | Sell | $5.38 | 25,000 | $134,482.50 | 1,108,719 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
GuruFocus.com
2 days ago
Ardelyx Inc (ARDX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Challenges
Thomson Reuters StreetEvents
2 days ago
Q4 2024 Ardelyx Inc Earnings Call
Zacks
2 days ago
Ardelyx (ARDX) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks
2 days ago
Ardelyx (ARDX) Meets Q4 Earnings Estimates
MT Newswires
2 days ago
Ardelyx Swings to Q4 Earnings, Revenue Rises
Associated Press Finance
2 days ago
Ardelyx: Q4 Earnings Snapshot
GlobeNewswire
2 days ago
Ardelyx Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
3 days ago
Ardelyx to Present at the TD Cowen 45th Annual Health Care Conference
Compare ARDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.